دورية أكاديمية
Self-Managed Medication Abortion: Implications for Clinical Practice.
| العنوان: | Self-Managed Medication Abortion: Implications for Clinical Practice. |
|---|---|
| المؤلفون: | Cirucci CA; Charlotte Lozier Institute, Arlington, VA, USA. |
| المصدر: | The Linacre quarterly [Linacre Q] 2023 Aug; Vol. 90 (3), pp. 273-289. Date of Electronic Publication: 2022 Dec 12. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: SAGE Country of Publication: United States NLM ID: 2985221R Publication Model: Print-Electronic Cited Medium: Print ISSN: 0024-3639 (Print) Linking ISSN: 00243639 NLM ISO Abbreviation: Linacre Q Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Publication: <2018->: Thousand Oaks, CA : SAGE Original Publication: St. Louis [etc.] |
| مستخلص: | Medication abortion represents more than 50 percent of abortions in the United States (US). Since its approval in the US in 2000, the Food and Drug Administration (FDA) has progressively relaxed the prescribing requirements such that currently, no office visit, in-person dispensing, or ultrasound is required. Obtaining medication for abortion online without medical supervision or evaluation is also possible. This article reviews the complications of medication abortion by examining major studies and delineates the risks specific to self-managed abortion to inform clinicians in caring for women. Summary: Medication abortion has become the most common abortion method in the United States. This document provides a detailed history of the relaxation requirements on medication abortion and reviews the major studies on medication abortion complications including a discussion of their limitations. Finally, the paper delineates the ease of access to medication abortion without a health care provider and the risks associated with self-managed abortion. This paper is intended to provide information for clinicians who likely will be encountering increasing number of patients with such complications. Competing Interests: The author declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. (© Catholic Medical Association 2022.) |
| References: | Contraception. 2013 Jan;87(1):26-37. (PMID: 22898359) Obstet Gynecol. 2021 Feb 1;137(2):e34-e41. (PMID: 33481530) Obstet Gynecol. 2018 Mar;131(3):e91-e103. (PMID: 29470343) Obstet Gynecol. 2022 May 1;139(5):771-780. (PMID: 35576336) Health Serv Res Manag Epidemiol. 2021 Nov 09;8:23333928211053965. (PMID: 34778493) Obstet Gynecol. 2015 Jul;126(1):12-21. (PMID: 26241251) Hum Reprod. 2011 Apr;26(4):927-32. (PMID: 21317416) Arch Dis Child Fetal Neonatal Ed. 2011 Mar;96(2):F84-5. (PMID: 21037283) J Clin Diagn Res. 2015 Jan;9(1):QC01-4. (PMID: 25738038) Obstet Gynecol. 2017 Aug;130(2):e57-e70. (PMID: 28742673) Contraception. 2015 Apr;91(4):269-73. (PMID: 25592080) Obstet Gynecol. 2009 Oct;114(4):795-804. (PMID: 19888037) Lancet. 2021 Oct 16;398(10309):1405-1406. (PMID: 34656220) Obstet Gynecol. 2004 Apr;103(4):729-37. (PMID: 15051566) Ann Pharmacother. 2005 Sep;39(9):1483-8. (PMID: 16046483) Med J Aust. 2012 Sep 3;197(5):282-6. (PMID: 22938126) Am J Obstet Gynecol. 2004 Apr;190(4):1077-81. (PMID: 15118645) J Midwifery Womens Health. 2010 Sep-Oct;55(5):462-7. (PMID: 20732668) BJOG. 2019 Aug;126(9):1094-1102. (PMID: 30869829) Contraception. 2019 Sep;100(3):173-177. (PMID: 31170384) Reprod Toxicol. 2013 Apr;36:98-103. (PMID: 23207166) BMC Womens Health. 2018 Sep 25;18(1):158. (PMID: 30253769) Contraception. 2013 Mar;87(3):331-42. (PMID: 23218863) Obstet Gynecol. 2015 Jul;126(1):22-8. (PMID: 26241252) Health Serv Res Manag Epidemiol. 2021 Dec 21;8:23333928211068919. (PMID: 34993274) Ann Pharmacother. 2006 Feb;40(2):191-7. (PMID: 16380436) Aust N Z J Obstet Gynaecol. 2021 Aug;61(4):607-611. (PMID: 33872380) MMWR Surveill Summ. 2021 Nov 26;70(9):1-29. (PMID: 34818321) J Immunol. 2008 Jun 15;180(12):8222-30. (PMID: 18523288) Obstet Gynecol. 2015 Jan;125(1):175-183. (PMID: 25560122) Acta Obstet Gynecol Scand. 2020 Apr;99(4):451-458. (PMID: 31883371) Lancet Reg Health Am. 2022 Jun;10:. (PMID: 35755080) Obstet Gynecol. 2013 Jan;121(1):166-71. (PMID: 23262942) Obstet Gynecol. 2017 Oct;130(4):778-782. (PMID: 28885427) Obstet Gynecol. 2020 Oct;136(4):e31-e47. (PMID: 32804884) Issues Law Med. 2021 Spring;36(1):3-26. (PMID: 33939340) Obstet Gynecol. 2017 May;129(5):e150-e154. (PMID: 28426621) |
| فهرسة مساهمة: | Keywords: Abortion; Abortion complications; Chemical Abortion; Gynecology; Medication Abortion; Mifepristone; Misoprostol; Obstetrical care; Roe v. Wade; Women’s reproductive health; Women’s reproductive issues |
| تواريخ الأحداث: | Date Created: 20231016 Latest Revision: 20240802 |
| رمز التحديث: | 20240802 |
| مُعرف محوري في PubMed: | PMC10566489 |
| DOI: | 10.1177/00243639221128389 |
| PMID: | 37841380 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher 
Full Text Finder | تدمد: | 0024-3639 |
|---|---|
| DOI: | 10.1177/00243639221128389 |